NOT FOR DISTRIBUTION
Header cover image

Market Cap

US$446.8m

Last Updated

2021/05/08 23:58 UTC

Data Sources

Company Financials +

Executive Summary

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. More Details


Snowflake Analysis

Excellent balance sheet and fair value.

Share Price & News

How has AC Immune's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: ACIU is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 9% a week.

Volatility Over Time: ACIU's weekly volatility (9%) has been stable over the past year.


Market Performance


7 Day Return

-9.0%

ACIU

-3.2%

US Biotechs

0.2%

US Market


1 Year Return

-20.5%

ACIU

24.4%

US Biotechs

49.9%

US Market

Return vs Industry: ACIU underperformed the US Biotechs industry which returned 24.4% over the past year.

Return vs Market: ACIU underperformed the US Market which returned 50.2% over the past year.


Shareholder returns

ACIUIndustryMarket
7 Day-9.0%-3.2%0.2%
30 Day-11.0%1.9%2.2%
90 Day-12.8%-10.6%4.2%
1 Year-20.5%-20.5%26.2%24.4%52.4%49.9%
3 Year-37.6%-37.6%27.0%20.5%63.7%53.4%
5 Yearn/a54.9%42.6%130.5%104.8%

Long-Term Price Volatility Vs. Market

How volatile is AC Immune's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is AC Immune undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: ACIU ($6.15) is trading below our estimate of fair value ($21.9)

Significantly Below Fair Value: ACIU is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: ACIU is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: ACIU is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate ACIU's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: ACIU is good value based on its PB Ratio (1.9x) compared to the US Biotechs industry average (3.5x).


Future Growth

How is AC Immune forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?

-4.0%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: ACIU is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: ACIU is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: ACIU is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: ACIU's revenue (10.5% per year) is forecast to grow faster than the US market (9.1% per year).

High Growth Revenue: ACIU's revenue (10.5% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: ACIU is forecast to be unprofitable in 3 years.


Past Performance

How has AC Immune performed over the past 5 years?

-21.0%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: ACIU is currently unprofitable.

Growing Profit Margin: ACIU is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: ACIU is unprofitable, and losses have increased over the past 5 years at a rate of 21% per year.

Accelerating Growth: Unable to compare ACIU's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ACIU is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-11.6%).


Return on Equity

High ROE: ACIU has a negative Return on Equity (-34.21%), as it is currently unprofitable.


Financial Health

How is AC Immune's financial position?


Financial Position Analysis

Short Term Liabilities: ACIU's short term assets (CHF220.5M) exceed its short term liabilities (CHF11.1M).

Long Term Liabilities: ACIU's short term assets (CHF220.5M) exceed its long term liabilities (CHF9.4M).


Debt to Equity History and Analysis

Debt Level: ACIU is debt free.

Reducing Debt: ACIU had no debt 5 years ago.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: ACIU has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if ACIU has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Dividend

What is AC Immune current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate ACIU's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate ACIU's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if ACIU's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ACIU's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of ACIU's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

5.0yrs

Average management tenure


CEO

Andrea Pfeifer (63 yo)

no data

Tenure

CHF1,746,000

Compensation

Prof. Dr. Andrea Pfeifer, Ph.D. has been the Chief Executive Officer of AC Immune SA since 2003. Prof. Dr. Pfeifer Co-founded AC Immune SA in April 2003. She serves as an Advisor and Chairwoman of BioMedPa...


CEO Compensation Analysis

Compensation vs Market: Andrea's total compensation ($USD1.93M) is about average for companies of similar size in the US market ($USD1.73M).

Compensation vs Earnings: Andrea's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: ACIU's management team is considered experienced (5 years average tenure).


Board Members

Experienced Board: ACIU's board of directors are considered experienced (3.5 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

AC Immune SA's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: AC Immune SA
  • Ticker: ACIU
  • Exchange: NasdaqGM
  • Founded: 2003
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$446.812m
  • Shares outstanding: 72.65m
  • Website: https://www.acimmune.com

Number of Employees


Location

  • AC Immune SA
  • Building B
  • EPFL Innovation Park
  • Lausanne
  • Vaud
  • 1015
  • Switzerland

Listings


Biography

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with p...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/05/08 23:58
End of Day Share Price2021/05/07 00:00
Earnings2021/03/31
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.